The predictive value of hypometabolism in focal epilepsy:a prospective study in surgical candidates by Tomás, José et al.
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
King’s Research Portal 
 
DOI:
10.1007/s00259-019-04356-x
Document Version
Peer reviewed version
Link to publication record in King's Research Portal
Citation for published version (APA):
Tomás, J., Pittau, F., Hammers, A., Bouvard, S., Picard, F., Vargas, M. I., ... Garibotto, V. (2019). The predictive
value of hypometabolism in focal epilepsy: a prospective study in surgical candidates. European Journal of
Nuclear Medicine and Molecular Imaging, 46(9), 1806-1816. https://doi.org/10.1007/s00259-019-04356-x
Citing this paper
Please note that where the full-text provided on King's Research Portal is the Author Accepted Manuscript or Post-Print version this may
differ from the final Published version. If citing, it is advised that you check and use the publisher's definitive version for pagination,
volume/issue, and date of publication details. And where the final published version is provided on the Research Portal, if citing you are
again advised to check the publisher's website for any subsequent corrections.
General rights
Copyright and moral rights for the publications made accessible in the Research Portal are retained by the authors and/or other copyright
owners and it is a condition of accessing publications that users recognize and abide by the legal requirements associated with these rights.
•Users may download and print one copy of any publication from the Research Portal for the purpose of private study or research.
•You may not further distribute the material or use it for any profit-making activity or commercial gain
•You may freely distribute the URL identifying the publication in the Research Portal
Take down policy
If you believe that this document breaches copyright please contact librarypure@kcl.ac.uk providing details, and we will remove access to
the work immediately and investigate your claim.
Download date: 10. Jul. 2020
1 
 
 
 
The predictive value of hypometabolism in focal epilepsy: a prospective study in surgical 
candidates 
 
José Tomás, MD1,2, Francesca Pittau, MD, PhD1,3, Alexander Hammers, MD, PhD4,5, Sandrine Bouvard, 
PhD6, Fabienne Picard, MD1,3, Maria Isabel Vargas, MD3,7, Francisco Sales, MD2, Margitta Seeck, MD, 
PhD1,3*, Valentina Garibotto, MD, PhD3,8* 
*these authors contributed equally to this work 
 
1 - EEG and Epilepsy Unit, Neurology Department, University Hospitals of Geneva, Geneva, Switzerland 
2 - Neurology Department, Coimbra Hospital and University Centre, Coimbra, Portugal 
3 - Faculty of Medicine of Geneva University, Geneva, Switzerland 
4 - The Neurodis Foundation, CERMEP Imagerie du Vivant, Lyon, France  
5 - King’s College London & Guy’s and St Thomas’ PET Centre, King’s College London, Division of Imaging 
Sciences and Biomedical Engineering, London, UK 
6 - Translational and Integrative Group in Epilepsy Research, Lyon Neuroscience Research Center, INSERM - 
U1028, CNRS - UMR5292, University Claude Bernard Lyon 1, Lyon, France 
7 - Neuroradiology Division, Diagnostic Department, University Hospitals of Geneva, Geneva, Switzerland 
8 - Nuclear Medicine and Molecular Imaging Division, Diagnostic Department, University Hospitals of Geneva, 
Geneva, Switzerland 
 
Corresponding author:  
Valentina Garibotto, MD, PD 
Division of Nuclear Medicine and Molecular Imaging, Geneva University Hospitals 
Rue Gabrielle-Perret-Gentil 4 
1205 Geneva, Switzerland 
valentina.garibotto@hcuge.ch 
Phone +41 79 5534459 - Fax +41 22 372 7169 
 
 
Title: 87 characters  
Abstract: 296 words 
Main manuscript: 3873 words  
Figures and tables: 2 + 4  
References: 55 
2 
 
 
 
 
 
 
 
Keywords  
FDG-PET; temporal epilepsy; extratemporal epilepsy; prognosis; predictive value; seizure onset zone 
 
ACKNOWLEDGEMENTS  
JT was supported by the “Egas Moniz” grant of the Neurology Portuguese Society. MS was supported by the SNF 
113766, SNF 180365, SNF 163398. Statistical help was provided by the Clinical Research Center, Geneva 
University Hospitals (Thomas Perneger). The reference database was provided by the CERMEP-Imagerie du 
vivant, Lyon, France.  
 
 
 
 
  
3 
 
 
 
ABSTRACT 
Purpose: FDG-PET is an established tool in presurgical epilepsy evaluation, however, it is most often used 
selectively in patients with discordant MRI and EEG results. Interpretation is complicated by the presence of 
multiple or remote hypometabolism, which casts doubt on the true localization of the seizure onset zone (SOZ) 
and might have a predictive value for surgical outcome. In the current study, we determined the sensitivity and 
specificity of PET localization prospectively in a consecutive unselected cohort of patients with focal epilepsy 
undergoing in-depth presurgical evaluation.  
Methods: 130 patients between 2006 and 2015 matched our inclusion criteria, of which 86 were operated (72% 
with favorable surgical outcome, Engel class I). We determined areas of focal hypometabolism using statistical 
parametric mapping and evaluated concordance with MRI, EEG or intracranial EEG. In the operated patient group, 
we used postsurgical outcome as gold standard for correctness of localization (minimum follow-up of 12 months). 
Results: PET sensitivity and specificity were both 95% in temporal lobe epilepsy (TLE; N=86) and 80% and 95% 
in extratemporal epilepsy (ETLE; N=44), respectively. Significant extratemporal hypometabolism was observed 
in 17 TLE cases (20%). Among patients with ETLE (n=44), temporal hypometabolism was observed in eight 
patients (18%).  
Among operated patients (N=86), 26 (30%) had hypometabolism extending beyond the SOZ.  The presence of 
unilobar hypometabolism, included in the resection, was predictive of complete seizure control (p=0.007), with an 
odds ratio of 5.4.  
Conclusions: In this group of non-selected patients with focal epilepsy, additional hypometabolic areas can be 
found in one out of five patients, including cases with “simple” lesional epilepsy, and should prompt further in-
depth evaluation of the correlation between EEG-findings, semiology and PET. Hypometabolism confined to the 
epileptogenic zone as defined by EEG and MRI is associated to favorable post-operative outcome in both TLE 
and ETLE.   
 
Abbreviations – FDG – 18F-fluorodeoxyglucose; PET – positron emission tomography; MRI – magnetic 
resonance imaging; TLE – temporal lobe epilepsy; ETLE – extratemporal lobe epilepsy; EEG – 
electroencephalogram; SOZ – seizure onset zone; HC – healthy control group; SPM – statistical parametric 
mapping 
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INTRODUCTION 
Epilepsy is one of the most frequent chronic neurological disorders, with an estimated prevalence in the general 
population of 6.38 per 1,000 persons [1]. Approximately one-third of the patients are drug-resistant, and in these 
cases, surgery is the only treatment that offers the possibility of a cure. Localizing the epileptogenic zone in 
presurgical patients requires a dedicated protocol of electrophysiological, structural and functional examinations, 
which often includes positron emission tomography (PET) imaging [2]. [18F]fluorodeoxyglucose-PET (FDG-PET) 
using positron-emitting isotopes is usually performed as an interictal study. FDG-PET contributes to the definition 
of the functional deficit zone [3] by revealing the area of reduced glucose metabolism. This zone can be larger 
than the epileptogenic cortex and can extend to remote areas [3, 4]. For example, in patients with a presumed 
seizure onset zone (SOZ) limited to the mesial temporal lobe due to hippocampal sclerosis, the hypometabolism 
often involves the whole temporal lobe and extends even beyond [5-7].Localization of the epileptogenic zone with 
PET is obtained in up to 90% of patients with temporal lobe epilepsy (TLE) and in up to 60% of patients with 
extratemporal lobe epilepsy (ETLE) [8].  
FDG-PET is particularly useful in TLE without Magnetic Resonance Imaging (MRI) abnormalities: patients with 
PET hypometabolism concordant with EEG findings benefit from surgery as much as patients with hippocampal 
sclerosis identified on MRI.[9, 10] In patients with ETLE, FDG-PET has been used as a guide in the search for 
subtle cortical dysplasia or to inform on the placement of intracranial electrodes [11]. 
However, FDG-PET can be misleading, as in some patients with ETLE, the hypometabolism is more prominently 
seen in the temporal lobe [8]. The factors previously reported as being associated with poorer prognosis were both 
hypometabolism remote from the epileptogenic zone [12] and a less severe hypometabolism of the epileptogenic 
zone [13]. However, most studies use PET in only selected cases, e.g. with negative MRI; therefore, the presence 
of remote hypometabolic areas could be due to the complexity of the case or lack of knowledge of EEG on seizure 
status before or during tracer injection.  
The present study has two main aims: 
1. To assess the occurrence of a hypometabolism confined to the lobe of the SOZ versus those providing 
ambiguous results, i.e. extending to other adjacent lobes, seen only in remote structures, or which were 
incorrectly normal.  
2. To evaluate the predictive value of the hypometabolic pattern observed, including a subset of patients 
treated surgically with follow up for at least 12 months.  
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Since all our patients received PET as part of the standard presurgical work-up, our series presents a unique 
opportunity to determine the yield of PET in drug-resistant epilepsy with TLE or ETLE in an unselected patient 
group. 
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MATERIALS AND METHODS 
Data collection – subjects  
This study was based on a prospectively collected database at a single institution, including a total of 346 
consecutive patients attending our epilepsy unit and undergoing PET scan imaging between 2006 and 2015. 
Informed consent was obtained from all individual participants included in the study and also from legally 
authorized representatives when minors were concerned. This study was approved by the Geneva Cantonal Ethical 
Commission, in agreement with the Declaration of Helsinki and its further amendments.  
We selected patients matching the following criteria:  
• Inclusion criteria: (i) > 6 years of age. Younger children have a more extended diffuse hypometabolism, 
which could lead to false positive findings;[14, 15] (ii) pharmacoresistant (persistence of seizures after at 
least two antiepileptic drugs, used at the maximal tolerated doses) and unifocal epilepsy based on the 
clinical history, semiology and laboratory tests mentioned below; (iii) pre-surgical evaluation consisting 
of at least MRI, FDG-PET and long-term video-EEG recording; (iv) PET scan acquired with a 
standardized protocol on a Siemens Biograph PET/CT tomograph (in our hospital since January 2006); 
(v) patients with no previous brain surgery. 
• Exclusion criteria: multilobar lesions visible on MRI, generalized or multifocal epilepsy, post-traumatic 
epilepsy, and progressive tumor, seizures 24 h before the tracer injection as determined by continuous 
monitoring before, during and after tracer injection. [16].  
A total of 130 patients (86 with TLE, 44 with ETLE) matched our criteria and were included in the present analysis 
(Fig. 1). 216 patients were excluded for the following reasons: not meeting inclusion criteria (n=48) or having 
exclusion criteria that could be associated with false positive findings, namely multilobar lesions visible on MRI, 
including hippocampal sclerosis (HS) in ETLE, generalized or multifocal non-lesional epilepsy, post-traumatic 
epilepsy, and progressive tumor and seizures within 24 h before the tracer injection (n=109) or having incomplete 
data (n=59). 
 
 
 
 
Definition of hypometabolism 
All PET images were analyzed visually by one expert reader (VG) who was not aware of the supposed localization 
of the epileptogenic zone based on clinical, EEG and MRI findings. All images were re-analyzed after co-
registration of the PET to the patient’s individual MRI (on a LEONARDO 3D reconstruction station, Siemens 
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Healthineers). Statistical parametric mapping (SPM8) was performed by comparing each individual PET image 
with a reference set of brain PET scans from 38 young healthy controls (38 subjects; 20 males, mean age 35 years, 
range 18-53) obtained from the CERMEP (Lyon) (© Copyright CERMEP and the authors, 2014. All rights 
reserved) to identify areas with significantly reduced glucose metabolism, as previously described [17] and 
detailed in the statistical analysis section below. The PET images of the controls were acquired on a ECAT EXACT 
HR+ scanner, which has physical properties comparable to those of the Siemens Biograph scanner used for patients 
[18].   
 
EEG recordings 
Conventional long-term video-EEG recording was performed on all patients with standard clinical EEG setups of 
31-37 electrodes (10/10 system). The placement of additional inferior longitudinal temporal electrodes was 
extremely important because of their selectivity to temporal lobe activity. Impedances were kept below 10 kΩ, the 
sampling rate was 256 Hz and band-pass filters were set to 0.1 and 120 Hz, with a vertex contact as the reference 
electrode. Patients were recorded 24 h before tracer injection and included in the current analysis if no clinical or 
subclinical seizures occurred during EEG monitoring, which comprised also the uptake of the tracer.  
 
Magnetic resonance imaging 
All patients had MRI scans as part of the pre-surgical evaluation. The scans were acquired with a 3T Trio scanner 
(Siemens AG, Germany) and were performed according to a standardized epilepsy protocol [19] using a 32-
channel brain coil: (a) axial T2-weighted fast spin-echo repetition time (TR) 7520 ms; echo time (TE) 114 ms; 
voxel size 0.5 x 0.4 x 3 mm (slice thickness); (b) 3D FLAIR (fluid-attenuated inversion recovery) TR 5000; TE 
419 ms; inversion time (TI) 1800; isotropic voxel size 0.9 x 0.9 x 0.9 mm); (c) 3D gradient echo T1 or T2, TR 
1750 ms; TE 2.29 ms; isotropic voxel size 0.7 x 0.7 x 0.7 mm; (d) diffusion-weighted imaging (DWI) TR 8000 
ms; TE 84 ms; 30 directions; (e) and axial arterial spin labelling (ASL) TR 4000 ms; TE 12 ms; voxel size 3.4 x 
3.4 x 4 mm (slice thickness). 3D images were analyzed in axial, coronal and sagittal planes. In 101/130 patients, 
the structural MRI showed a pathological result, indicating an epileptogenic lesion, specifically HS in 45 TLE 
subjects; the other 29/130 patients had normal MRI findings (12 with a final diagnosis of TLE). 
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Positron emission tomography acquisition 
FDG-PET was performed using 2-[18F]fluoro-2-deoxy-d-glucose in all patients in the interictal phase (at least 24 
hours after the last seizure). Patients, having fasted at least 6 hours, received an injection of 200 MBq or a weight-
adapted dose in children, according to the EANM pediatric card (http://www.eanm.org/content-
eanm/uploads/2017/01/EANM_Dosage_Card_040214.pdf) of [18F]FDG, while resting in a quiet and dimly lit 
room. In all patients, the EEG was continuously monitored during the thirty minutes uptake time to exclude 
subclinical seizures, leading potentially to false negative or positive findings. PET images were acquired on 
tomographs equipped with lutetium oxyorthosilicate (LSO) crystals, namely the Siemens Biograph Hi-Rez, 
TruePoint or mCT PET/CT systems, in 3D mode.  Scan duration was twenty minutes. 
 
Temporal lobe epilepsy and extratemporal lobe epilepsy 
Localization of the epileptogenic zone was based on anatomo-electro-clinical correlations (i.e., correlations 
between ictal semiology, electro-physiological activity, and structural lesion) [20] by a neurologist (FP) blinded 
to the results of the PET examination. TLE was defined as having a focus in the mesial temporal lobe and/or 
temporal pole. The remainder of cases were identified as ETLE, including lateral and posterior temporal, parietal, 
occipital and frontal lobe epilepsy. 
 
Surgery 
All cases were discussed in our weekly interdisciplinary case conference. A total of 86 of the 130 (66%) patients 
underwent temporal or extratemporal surgical intervention, while 44 were not operated upon for different reasons: 
epileptic focus in eloquent areas with unclear cost-benefit from a respective surgery (30), severe psychiatric co-
morbidities interfering with the patient’s decision making (10), or refusal of surgery on the part of the patient after 
considering the risks (4).   
 
Performance of PET as a test 
The epileptogenic zone was defined on the concordance of clinical information (semiology), EEG and MRI 
findings. Intracranial EEG was performed in 29 patients (22% of the total sample; X operated) and was considered 
for the present analysis. Out of the 29 patients with intracranial EEG, 14 were implanted with depth electrodes 
only, two were implanted with subdural electrodes only, and 12 were implanted with both depth and subdural 
electrodes. Twenty had bilateral explorations, while the explorations were limited to one hemisphere in nine 
patients. 
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Using standardized PET analysis with SPM, as described above, the degree of concordance of the PET results with 
the presumed SOZ was described as follows: 
• Concordant (C): if the hypometabolism is concordant and confined to the lobe of the presumed SOZ; 
• Concordant Plus (C+): if the hypometabolism extends from the epileptogenic zone to adjacent lobes; 
• Multifocal (M): if multiple clusters of hypometabolism in non-adjacent lobes exist; 
• Remote (R): if the hypometabolism is located outside the presumed SOZ lobe; 
• Normal (N): no significant hypometabolism, either at the presumed SOZ or at elsewhere. 
Examples for the different categories TLE and ETLE patients are shown in Fig. 2. 
Analyses were performed by dichotomizing between category C and the remaining categories. 
 
Seizure outcome after epilepsy surgery 
All 86 operated patients were seen postoperatively by the neurosurgeon and neurologist or neuropediatrician. The 
mean follow-up period was 30.5+/-22.9 months (range 12-108 months). Seizure outcomes were classified 
according to the classification proposed by Engel: Class I: free of disabling seizures (specifically including patients 
who were seizure free after surgery –Ia-, with nondisabling simple partial seizures only since surgery –Ib-, with 
some disabling seizures after surgery, but free of disabling seizures for at least 2 years –Ic-, and patients with 
generalized convulsions with anti-epileptic drug discontinuation only –Id-); Class II: rare disabling seizures 
("almost seizure-free"), i.e., seizure decrease of > 90%; Class III: worthwhile improvement (seizure decrease of 
50-90%); Class IV: no worthwhile improvement (< 50% decrease). In the present study, patients free of disabling 
seizures (Engel class I) were compared to all other patients (Engel class II-IV). [21] 
 
Statistical analysis 
PET images were processed using Statistical Parametric Mapping (Wellcome Department of Cognitive Neurology, 
London, UK, version 8 – SPM8).  After normalization to the CERMEP FDG-PET template (© Copyright 
CERMEP and the authors, 2014. All rights reserved), with an isotropic voxel size of 2 mm and smoothing (8 mm), 
individual patients were compared to controls in a 2-sample t test using proportional scaling to global activity and 
age as covariate. The resulting statistical parametric map was thresholded at p<0.01 (uncorrected), and a minimum 
cluster extent of 40 voxels was considered, taking into account only true hypometabolic clusters, i.e., abnormalities 
with cortical locations and concordant with subsequent visual analysis of fused PET/MRI data [17]. 
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Hypometabolic clusters were described quantitatively by their size (number of voxels above the threshold) and 
severity (highest Z score in the cluster).  
We also correlated cluster size and severity of hypometabolism with different clinical variables using Spearman’s 
correlation. 
A logistic regression analysis was used to predict the presence of a favorable (Engel class I) outcome, including 
the type of epilepsy (TLE and ETLE) and the type of hypometabolism (C vs. others) as variables in the analysis. 
We also tested the benefits of gender, age at onset, age at PET and lesional epilepsy as predictors. 
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RESULTS 
The main characteristics and the demographic data of the 130 patients (66 female) are displayed in Table 1. The 
mean age of the patient group was 27.4±13.5 years (range 6-60), the mean duration of epilepsy was 15.0±11.5 
years (range 0-53), and the age of onset was 12.8±10.5 years (range 0-46). 
Among lesional epilepsy, the lesions consisted in hippocampal sclerosis (45 cases), cortical dysplasia (34, of which 
25 operated, including 15 FCD type II, 3 FCD type I, 3 cases with cortical dysplasia not otherwise specified and 
4 with mild malformations of cortical development), non-progressive tumors (14, of which 10 operated including 
6 dysembryoplastic neuroepithelial tumor, 2 oligodendrogliomas WHO grade II and 2 gangliogliomas WHO grade 
I), polymicrogyria (1), hemimegalencephaly (1), post-traumatic (2), vascular lesions (3) and post-infectious lesions 
(1).  
 
 
Localizing value of PET  
In TLE patients, including operated and non-operated patients, both the sensitivity and specificity of interictal PET 
were 95%. For ETLE patients, the sensitivity was 80%, and the specificity was 95%. Table 2 shows the distribution 
of metabolic patterns among TLE (with and without HS) and ETLE patients. Hypometabolism only at remote sites 
(metabolic pattern R) was found in only one patient with TLE and ETLE each (1.5%; one lesional left temporal 
epilepsy with right frontal hypometabolism only, one case with non-lesional right frontal epilepsy but bilateral 
temporal hypometabolism), i.e., this constellation is rarely observed. Entirely normal PET, i.e., without any 
hypometabolism, was found in 3/86 (3%) of TLE and 8/44 (18%) of ETLE patients (p=0.007) and in 5/101 (5%) 
of patients with lesional and 6/29 (21%) of patients with non-lesional epilepsy (p=0.015).  
There were no significant differences in the distribution of “metabolic patterns”, namely C, C+, M, R and N, 
between ETLE and TLE, nor between TLE patients with and without HS (p=0.08 and p=0.31).  
 
The analysis of the different hypometabolic regions in TLE patients showed that five patients had extratemporal 
hypometabolism in more than one area (n=22 hypometabolic foci in total). These were noted in frontal, insular, 
parietal/temporal posterior and occipital cortex. Overall, remote hypometabolism was more frequent in the frontal 
lobe (12/22; 55%) and ipsilateral to the side of the temporal focus (18/22 - 82%; an example is provided in Fig. 
2). Among patients with HS, we observed additional hypometabolism outside the SOZ lobe in 14 out of 45 patients 
with HS, most commonly consisting in contralateral temporal hypometabolism (7 subjects).   
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In ETLE, additional temporal hypometabolism was observed in 8/44 of the patients (18%), 5/8 (62%) ipsilateral 
and 3/8 (38%) bilateral. Temporal hypometabolism was associated with frontal epilepsy in three cases (one 
bilateral), with parietal epilepsy in two cases (one bilateral), and occipital epilepsy in three cases (one bilateral, 
Fig. 2).   
 
No differences in age of onset, age at evaluation and duration were found between C patients and the other 
hypometabolism categories in the TLE and ELTE groups. There was no significant difference between TLE and 
ETLE groups regarding the cluster size of the hypometabolism corresponding to SOZ versus those which showed 
hypometabolism beyond SOZ (p=0.245).  
 
 
Predictive value of PET in operated patients 
A total of 86 patients were operated (62 with TLE, 24 with ETLE), allowing to determine the predictive value on 
postoperative outcome. The patient numbers who post-surgically achieved freedom from disabling seizures were 
53/62 (85%) among operated TLE patients and 19/24 (79%) among operated ETLE patients (p=0.477).  
When considering only operated patients, the hypometabolic patterns among TLE patients were distributed as 
follows: 43 C (69%), 7 C+ (11%), 11 M (18%) and 1 R (2%). Extratemporal hypometabolic areas (16) were most 
frequently observed in the ipsilateral frontal lobe (7, 44%).  
Among ETLE, there were 16 C (67%), 1 C+ (4%), 5 M (21%) and 2 N (8%) The extra-SOZ hypometabolic sites 
(8) were most frequently seen in the ipsilateral temporal anterior region (5; 62%). There were no significant 
differences between the frequency of fully concordant or other hypometabolism between the TLE and ETLE 
groups. 
 
The presence of unifocal hypometabolism limited to the epileptogenic zone (C) had a favorable predictive value 
compared to the remaining groups (p=0.007), with a high odds ratio of 5.4 (95% confidence interval – CI - 1.6 – 
18.3), i.e. 6.2 for TLE and 4.2 for ETLE when analyzing both groups separately. The distribution of metabolic 
patterns and post-operative outcome is summarized in Table 3. The odds ratio estimate was unchanged (5.4; 95% 
CI 1.5-19.3) when including gender, age at onset, age at PET and lesional vs. non-lesional epilepsy in the model.  
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DISCUSSION 
The results of our prospective study show, in a large consecutive cohort, two main findings: a) hypometabolism 
beyond the presumed SOZ is not rare and occurs with a similar frequency in both TLE and ETLE surgical 
candidates, b) hypometabolism outside the SOZ contains a significant predictive value regarding surgical outcome.   
 
 
Localizing value of PET abnormalities 
In the literature, localizing information ranged from 60 to 90% in the patients with TLE and from 30 to 60% in the 
patients with ETLE [8, 22-29]. Additional areas of hypometabolism are frequently reported and seen in 10-43 % 
of the subjects. However, these studies applied PET in selected patient groups, so the true frequency of additional 
hypometabolic foci and non-concordant findings were not known.  
In our study of non-selected patients, we observed temporal hypometabolism in 18% of ETLE subjects and 
extratemporal hypometabolism, mostly in the ipsilateral frontal lobe, in 20% of TLE patients [30-32]. This is at 
the lower end of the frequency of non-localizing findings previously reported, ranging from 20% to 67% [8, 30]. 
Apart from the selection criteria, the studies differed in analysis tools and patient populations (e.g. number of 
children or ETLE patients). We like to stress that in contrast to the present observation, many previous studies did 
not offer EEG monitoring before and during cerebral tracer absorption [15, 24, 27], thus the presence of subclinical 
seizures is unknown and could have added to the variability of findings.  
The occurrence of additional and remote abnormalities in focal epilepsy represents a diagnostic dilemma, which 
occurs in 1 out of 5 patients approximately. This calls for meticulous comparison of the site of PET abnormality 
with the semiology, structural anomalies, ictal, interictal EEG findings. It is of note that even in “simple” lesional 
focal epilepsy, 5/130, i.e. 4%, have an entirely normal PET. 
 
The precise relationship between SOZ and PET hypometabolism was studied in patients with intracranial 
electrodes and suggests a complex association. Two studies in pediatric patients undergoing subdural EEG 
monitoring showed that the ictal onset electrodes were located over the most hypometabolic area as well as over 
adjacent regions within 2 to 3 cm. However, a large proportion of hypometabolic regions had no early seizure 
involvement [33, 34]. A previous study in cavernous angioma suggested deafferentation as a possible mechanism 
[35]. 
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Predictive value of remote metabolic abnormalities on surgical outcome 
Our number of patients without seizures post-operatively compares favorably with the numbers in the literature 
[36, 37].  
In our series, the pattern of hypometabolism carried predictive information with respect to surgical outcome, in 
agreement with the majority of the studies available in the literature, which are summarized in Table 4. Overall, 
the majority of studies in TLE concordantly showed that PET patterns carry a predictive information, with a 
more severe hypometabolism in the SOZ and the absence of extra-SOZ hypometabolism associated with a better 
prognosis [13, 25, 30, 38-43]. In ETLE the results are instead discordant, with four studies showing a significant 
predictive value for a positive PET [12, 26, 44, 45] and two studies failing to show such a predictive value [46, 
47]. 
In our data we found that hypometabolism confined to the lobe of the SOZ (C), assessed with a combined visual 
and semiquantitative approach, was a significant predictor of seizure-free postoperative outcome in both TLE 
and ETLE. Importantly, in our series, gender, age at onset, age at PET and the presence of a lesion at MRI had 
no additional predictive value. 
 
Possible explanations for a worse outcome if remote and non-concordant hypometabolism are present, could 
relate to diffuse seizure spreading or incorrect presurgical localization of the resected region. Fast propagation to 
other areas, as determined by EEG, usually indicates a more pathological and widespread network, with lower 
chances to benefit from surgery. This might be due to the type of pre-existing epilepsy or a consequence of long-
standing epilepsy. Additional areas of hypometabolism then might reflect these constitutional or acquired 
conditions. We are not aware of prospective studies using follow-up PETs in patients with chronic epilepsy to 
distinguish between these two conditions. Alternatively, the additional or remote hypometabolism represents the 
true focus, despite its smaller size, and harbors subtle structural anomalies. Independent of the underlying 
pathophysiological mechanism, our results suggest that incongruent findings between the PET localization and 
SOZ as determined by EEG and semiology should be considered as “red flags”. They call for further 
investigations, if there is no epileptogenic MRI-lesion with concordant semiology, including electric source 
localization, ictal SPECT or intracranial EEG. 
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Non-FDG PET tracers as predictors of surgical outcome 
Besides FDG-PET, other tracers have been tested, mainly in research settings, in the presurgical evaluation of 
epilepsy, targeting other pathophysiologic and neurotransmission pathways, for example GABA-ergic, 
glutamatergic, serotonergic and dopaminergic neurotransmission or neuroinflammation, as recently reviewed [48, 
49]. Only a minority of studies, however, tested specifically the predictive value of these tracers for surgical 
outcome, mainly in TLE. An association was found between worse post-operative outcome and periventricular 
white matter increase of [11C]flumazenil-PET binding, a GABA-A targeting radioligand, in patients with TLE 
and hippocampal sclerosis, possibly due to the presence of an increased concentration of heterotopic neurons [50, 
51]. The probability of being seizure-free in TLE has also been associated with reduced serotonin 1A receptor 
density, as measured with 18F-FCWAY, and reduced metabotropic glutamate receptor type 5 density, as measured 
with 11C-ABP688 [52, 53]. A study with 11C-alpha-methyl-triptophan, a tracer of serotonin synthesis which helps 
identifying epileptogenic tubers in patients with tuberous sclerosis, showed that the resection of tubers with a 
higher uptake was a good predictor of surgical outcome [52, 54]. Finally, one study investigated the expression of 
P-glycoprotein, which can be associated with drug-resistant epilepsy, by the tracer [11C]verapamil: an optimal 
post-surgical outcome was associated with higher Pgp function before surgery and larger Pgp reduction 
postoperatively [55].  
 
CONCLUSION 
Extratemporal hypometabolism in TLE and temporal hypometabolism in ETLE occurred in about 18-20% of the 
cases, i.e. 1 in 5 patients, and were more frequently observed in the same hemisphere (82% for ipsilateral 
extratemporal hypometabolism in TLE; 73% for ipsilateral temporal hypometabolism in ETLE). These 
abnormalities are not only diagnostically challenging but also have negative predictive meaning in TLE and ETLE, 
as they are associated with a greater risk of post-surgical disabling seizures. Our prospective study confirms 
previous retrospective observations in TLE and ETLE suggesting that careful analysis of the metabolic pattern, 
also beyond the presumed SOZ, has predictive value, even in “simple” lesional cases. 
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Figure legends 
 
Fig. 1  
Flow diagram of patient enrolment. 
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Fig. 2  
Individual examples of metabolic patterns identified in temporal lobe epilepsy (TLE) and extratemporal lobe 
epilepsy (ETLE) study participants (colour bars indicate T values, individual maps are thresholded at p<0.01, 
k>40). The figure reports the presumed SOZ localization and the surgical outcome for operated patients.  
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Table 1. Demographic data of healthy controls (HC) and patients with temporal (TLE) and extratemporal lobe 
epilepsy (ETLE). ETLE patients were classified as frontal (n=28), parietal (n=7), occipital (n=3), multilobar (n=4) 
and others with remaining extratemporal focus (n=2).  
 HC (n=38) TLE (n=86) ETLE (n=44) TLE vs. ETLE (p) 
Female, n (%) 18 (47%) 45 (52%) 21 (48%) 0.712 
Age at evaluation, 
mean±sd (years) 
35.2 ± 10.2 29.1±12.8  25.2±14.5  0.06 
Age of onset, mean±sd 
(years) 
- 14.6±10.4   9.3±9.7  0.001 
Lesional*, n (%) - 74 (86%) 27 (61%) 0.001 
Underwent presurgical 
invasive evaluation, n 
(%) 
- 22 (26%) 8 (18%) 0.387 
Underwent surgery with 
curative intent, n (%) 
- 62 (72%) 24 (55%) 0.045 
Post-surgical outcome, 
Engel Class, n (I/II-IV) 
- 53 (85%) / 9 (15%) 19 (79%) / 5 (21%) 0.522 
Follow-up duration, 
mean±sd (months) 
- 32±24.4  26.4±18.6  0.351 
 
Abbreviations: HC, healthy controls; TLE, temporal lobe epilepsy; ETLE, extratemporal lobe epilepsy;*HS 
was present in 45 TLE, and in none of the ETLE, as the presence of HS in ETLE was considered an exclusion 
criterion, as specified in the Methods.  
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Table 2. Metabolic patterns in TLE and ETLE patients. 
 
C C+ M R N 
TLE 55 (64%) 11 (13%) 16  (19%) 1 (1%) 3 (3%) 
TLE 
 with HS, n=45 
31 (69%)  5 (11%) 8 (18%) 1 (2%) 0 
TLE without 
HS, n= 41 
24 (59%) 6 (15%) 8 (20%) 0 3 (7%) 
ETLE, n=44 23 (52%)  5 (11%) 7 (16%) 1 (2%) 8 (18%) 
Abbreviations: TLE, temporal lobe epilepsy; ETLE, extratemporal lobe epilepsy; SOZ, seizure onset zone; C, 
concordant; C+, concordant plus; M, multifocal; R, remote; N, normal; HS, hippocampal sclerosis.  
 
 
 
 
 
Table 3. Predictive value of PET pattern in operated patients 
 Engel Class I 
Number (TLE/ETLE) 
Engel Class II-IV 
Number (TLE/ETLE) 
Hypometabolism confined to the 
SOZ 
(C) 
54 
(40/14) 
5 
 (3/2) 
Hypometabolism outside the 
SOZ or negative  
(C+, M, R, N) 
 18  
(13/5) 
9  
(6/3) 
Abbreviations: TLE, temporal lobe epilepsy; ETLE, extratemporal lobe epilepsy; SOZ, seizure onset zone; C, 
concordant; C+, concordant plus; M, multifocal; R, remote; N, normal. 
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Table 4. Main research papers evaluating the predictive value of FDG PET for thesurgical outcome 
 
 Study Number of 
operated 
patientstype 
of epilepsy 
Outcome evaluated Analysis Main result 
TLE Guedj et al. 
2015 [13] 
30 operated 
TLE 
Engel class > 2 
years (I-II vs. III-
IV) 
SPM Better outcome in 
more severe 
hypometabolism 
Salanova et 
al., 2001 
[25] 
69 TLE 
operated 
Engel class > 2 
years, class I vs 
higher 
Visual (2 readers) More frequent 
hypometabolism (vs. 
normal scan in patient 
with better outcome) 
Wong et al., 
2010 [30] 
64 mTLE Engel > 2 years Visual + SPM 
(temporal/contiguous/remote) 
Remote negative 
prognostic impact 
Radtke et 
al., 1993 
[38] 
30 TLE Seizure free > 2 
years 
Visual Presence of 
hypometabolism 
associated with a 
positive outcome 
Knowlton et 
al., 1997 
[39] 
25 unilateral 
TLE 
Engel class (I-II vs 
higher > 1.5 years) 
Visual HS and 
hypometabolism of 3 
or more temporal 
subregions associated 
with good outcome 
Dupont et 
al., 2000 
[40] 
30 MTLE Engel > 2 years Region based analysis in 
temporal and frontal regions 
Better outcome in 
stronger asymmetry 
Struck et al., 
2011 [41] 
34 TLE ILAE class > 6 
months 
Class I vs higher 
Visual FDG unilateral 
temporal only 
predictor (as compared 
with MRI and EEG of 
outcome 
Higo et al., 
2016 [42] 
40 mTLE Engel at 1 and 2 
years (I-II vs III-IV 
Visual and 3D-SSP Better outcome in 
more asymmetric 
temporo-mesial 
metabolism. 
None with 
extratemporal 
hypometabolism 
Choi et al., 
2003 [43] 
47 mTLE Engel > 5 years Visual (agreement of 2 
readers) 
Negative outcome for 
extratemporal 
hypometabolism 
ETLE Wong et al., 
2012 [12]  
68 neocortical 
epilepsy 
Engel > 2 years SPM: concordant vs remote Remote negative 
prognostic impact 
Lee et al., 
2005 [26] 
89 neocortical 
epilepsy 
Engel class > 2 
years 
Visual + SPM PET concordant in 
44% of the cases. 
Localizing/concordant 
PET more frequently 
associated with a 
Engel I outcome 
Kim et al., 
2017 [44] 
109 
nonlesional 
neocortical 
epilepsy 
Engel > 10 years 
(class I vs II-IV) 
Visual + SPM Localizing FDG PET 
associated with better 
outcome 
Desarnaud 
et al., 2018 
[45] 
103 focal 
cortical 
Engel > 2 years Visual (fusion with MRI) Higher Engel I  and Ia 
in PET positive cases, 
25 
 
 
 
dysplasia type 
2 
with OR lower than 
MRI 
Kim et al., 
2004 [46] 
26 parietal 
lobe epilepsy 
Engel class > 1 year SPM (considering only the 
most severe abnormality) 
No difference in 
positivity rate between 
seizure free and non-
seizure free 
Kogias et 
al., 2017 
[47] 
26 3T MRI 
neg patients  
(10 TLE/16 
ETLE) 
Engel class > 1 year Visual (two readers) Lateralizing PET was 
correlated with better 
outcome in TLE, not 
in ETLE 
Abbreviations: TLE, temporal lobe epilepsy; ETLE, extratemporal lobe epilepsy; OR, odds ratio; SPM, 
statistical parametric mapping; HS, hippocampal sclerosis. 
 
 
